Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 10/20 | 0.81 |
| ▸ | ACE | P12821 | 4/20 | 0.81 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lbq-657 SCHEMBL7433849 | 0.90 | MME (1.00) | MMEACEMMEL1 | |
| Lbq-657 SCHEMBL9565416 | 0.90 | MME (1.00) | MMEACEMMEL1 | |
| Lbq-657 SCHEMBL391633 | 0.90 | MME (1.00) | MMEACEMMEL1 | |
| Lbq-657 SCHEMBL1908575 | 0.90 | MME (1.00) | MMEACEMMEL1 | |
| Lbq-657 SCHEMBL489122 | 0.90 | MME (1.00) | MMEACEMMEL1 | |
| SCHEMBL17169605 | 0.87 | MME (0.80) | MMEACEMMEL1 | |
| SCHEMBL22556623 | 0.87 | MME (0.80) | MMEACEMMEL1 | |
| SCHEMBL18952136 | 0.87 | MME (0.80) | MMEACEMMEL1 | |
| SCHEMBL14891103 | 0.86 | MME (1.00) | MMEACEMMEL1 | |
| SCHEMBL14891104 | 0.86 | MME (1.00) | MMEACEMMEL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3325013-A1 | STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2018-05-30 | — | — | EP | claimed |
| WO-2017029261-A1 | COMBINATION DRUG COMPRISING FINERENONE AND AN NEP-INHIBITOR (SACUBITRIL) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-23 | — | — | WO | claimed |
| WO-2017013010-A1 | STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-26 | — | — | WO | claimed |
| EP-3325013-A1 | STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2018-05-30 | — | — | EP | disclosed |
| WO-2017029261-A1 | COMBINATION DRUG COMPRISING FINERENONE AND AN NEP-INHIBITOR (SACUBITRIL) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017013010-A1 | STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-26 | — | — | WO | disclosed |